Alcohol Use Disorder Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight

The Alcohol Use Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alcohol Use Disorder pipeline products will significantly revolutionize the Alcohol Use Disorder market dynamics.

DelveInsight's "Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alcohol Use Disorder, historical and forecasted epidemiology as well as the Alcohol Use Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alcohol Use Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Alcohol Use Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alcohol Use Disorder Market Forecast
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Alcohol Use Disorder Market Report:
• The Alcohol Use Disorder market size was valued ~USD 620 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In February 2025, A Phase II placebo-controlled trial suggests that a once-weekly injection of semaglutide may help reduce alcohol cravings and decrease alcohol consumption in individuals with alcohol use disorder (AUD). Conducted by the University of North Carolina at Chapel Hill (NCT05520775), the nine-week study found that nearly 40% of participants receiving semaglutide reported a noticeable reduction in overall alcohol cravings.
• In November 2024, Adial Pharmaceuticals received a patent from the United States Patent and Trademark Office, covering an expanded range of genotype combinations identified through its proprietary genetic diagnostic for the targeted treatment of AUD with AD04, its lead investigational drug. Additionally, in the same month, the company reported positive topline results from the pharmacokinetics (PK) study of AD04, which will aid in refining the study design for the upcoming Phase 3 clinical trial.
• In August 2024, Adial Pharmaceuticals partnered with Boudicca to support the development of technical and regulatory strategies for its companion diagnostic genetic test.
• In July 2024, Adial Pharmaceuticals filed a new patent application for AD04, aimed at treating Alcohol Use Disorder, which, if approved, could secure protection for its key assets until at least 2044. In the same month, the company progressed to the second cohort in its pharmacokinetics study of AD04 for AUD.
• In July 2024, The US FDA approved the IND application for the CMND-100 oral capsule, allowing the company to commence a Phase I/IIa clinical trial in the US for Alcohol Use Disorder (AUD). Additionally, Clearmind Medicine formed a strategic partnership with JS First Sdn. Bhd. to identify global manufacturers and distributors for its MEAI-based alcohol substitute beverages, supporting its international expansion. In June 2024, Adial Pharmaceuticals published the previously reported findings from its Phase III ONWARD study in the *European Journal of Internal Medicine*.
• Among the 7MM countries the highest Alcohol Use Disorder market size was in the United States accounting for ~USD 475 million in 2023.
• According to DelveInsight's estimates, Germany had the largest AUD market among the EU4 and the UK in 2023, with nearly USD 36.5 million, followed by the UK with approximately USD 26.6 million. Spain had the smallest market, at around USD 19.3 million.
• According to DelveInsight's analysis, there were approximately 25,312,290 diagnosed prevalent cases of AUD in the 7MM over a 12-month period in 2023, and this number is expected to rise by 2034.
• Based on DelveInsight's analysis, the US accounted for approximately 58.68% of the total 12-month diagnosed prevalent cases of AUD in the 7MM in 2023, and this figure is expected to increase by 2034.
• DelveInsight's epidemiology model for AUD indicates a male predominance in the 7MM, with an estimated 9,354,525 male cases and 5,498,643 female cases in the US in 2023.
• In 2023, Germany had the highest number of 12-month diagnosed prevalent cases of AUD among the EU4 and the UK, with approximately 2,532,809 cases, whereas Spain had the lowest, with nearly 1,338,496 cases. These numbers are expected to rise by 2034.
• In 2023, the 12-month diagnosed prevalent population of AUD in Japan was approximately 1,156,355 cases, with this number expected to change over the study period (2020-2034).
• The AUD market includes a variety of off-label and generic medications such as gabapentin, varenicline, benzodiazepines, memantine, ondansetron, aripiprazole, and suvorexant, in addition to four FDA-approved medication-assisted treatments: Acamprosate, ANTABUSE (disulfiram), REVIA (oral naltrexone), and VIVITROL (extended-release injectable naltrexone). Furthermore, TOPAMAX (topiramate) is recommended by the National Institute on Alcohol Abuse and Alcoholism for AUD treatment.
• Key Alcohol Use Disorder Companies: Corcept Therapeutics, Adial Pharmaceuticals, MediciNova, Clearmind Medicine, Bioprojet, Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others
• Key Alcohol Use Disorder Therapies: CORT 118335 (miricorilant), AD04 (ondansetron), MN-166 (ibudilast), CMND-100, BP1.3656, Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others
• The Alcohol Use Disorder epidemiology based on gender analyzed that males are more affected with Alcohol Use Disorder (AUD) as compared to females

Alcohol Use Disorder Overview
Alcohol Use Disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol consumption despite adverse social, occupational, or health consequences. It encompasses a range of drinking behaviors, from mild to severe, and is sometimes referred to as alcoholism.

Get a Free sample for the Alcohol Use Disorder Market Report:
https://www.delveinsight.com/report-store/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alcohol Use Disorder Market
The dynamics of the Alcohol Use Disorder market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"Alcohol use disorders are an important cause of morbidity and mortality. Despite the National Institute on Alcohol Abuse and Alcoholism (NIAAA) recommendations that medications be considered for patients with alcohol dependence, the mainstay of treatment has been counseling"

Alcohol Use Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alcohol Use Disorder Epidemiology Segmentation:
The Alcohol Use Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Alcohol Use Disorder
• Prevalent Cases of Alcohol Use Disorder by severity
• Gender-specific Prevalence of Alcohol Use Disorder
• Diagnosed Cases of Episodic and Chronic Alcohol Use Disorder

Download the report to understand which factors are driving Alcohol Use Disorder epidemiology trends @ Alcohol Use Disorder Epidemiological Insights
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alcohol Use Disorder market or expected to get launched during the study period. The analysis covers Alcohol Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alcohol Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Alcohol Use Disorder treatment, visit @ Alcohol Use Disorder Medications
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alcohol Use Disorder Therapies and Key Companies
• CORT 118335 (miricorilant): Corcept Therapeutics
• MN-166 (ibudilast): MediciNova
• CMND-100: Clearmind Medicine
• BP1.3656: Bioprojet
• Pear-009: Pear Therapeutics
• CYB003: Cybin
• Nezavist: Lohocla Research
• BXCL501: BioXcel Therapeutics
• PT150: Pop Test Oncology
• DCR-AUD: Dicerna Pharmaceuticals
• ASP8062: Astellas Pharma
• KT 110: Kinnov Therapeutics
• Ibudilast: MediciNova
• AD04 : Adial Pharmaceuticals

Alcohol Use Disorder Pipeline Market Drivers
• Increasing Awareness
• Increasing research and development
• Initiative taken by market players

Alcohol Use Disorder Pipeline Market Barriers
• Less Treatment Utilization
• Side Effects of the Current Alcohol Use Disorder Therapies

Scope of the Alcohol Use Disorder Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alcohol Use Disorder Companies: Corcept Therapeutics, Adial Pharmaceuticals, MediciNova, Clearmind Medicine, Bioprojet, Pear Therapeutics, Cybin, Lohocla Research, BioXcel Therapeutics, Pop Test Oncology, Dicerna Pharmaceuticals, Astellas Pharma, Kinnov Therapeutics, MediciNova, Adial Pharmaceuticals, and others
• Key Alcohol Use Disorder Therapies: CORT 118335 (miricorilant), AD04 (ondansetron), MN-166 (ibudilast), CMND-100, BP1.3656, Pear-009, CYB003, Nezavist, BXCL501, PT150, DCR-AUD, ASP8062, KT 110, Ibudilast, AD04, and others
• Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and Alcohol Use Disorder emerging therapies
• Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and Alcohol Use Disorder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Alcohol Use Disorder Unmet Needs, KOL's views, Analyst's views, Alcohol Use Disorder Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.